다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Korean journal of Hematology, v.45 no.2, 2010년, pp.136 - 138
Lim, Young-Hyo (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Lee, Young Yiul (Division of Hematology) , Kim, Jae Hoon (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Shin, Jinho (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Lee, Jae Ung (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Kim, Kyung-Soo (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Kim, Soon-Kil (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Kim, Jeong Hyun (Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.) , Lim, Heon Kil (Division of Cardiology, Department of Internal Medicine, College of Medicine, H)
AI-Helper
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide ...
1 Tefferi A Chronic myeloid disorders: Classification and treatment overview Semin Hematol 2001 38 1 Suppl 2 1 4 11242595
2 Löfvenberg E Wahlin A Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea Eur J Haematol 1988 41 375 381 3197824
3 Gisslinger H Chott A Scheithauer W Gilly B Linkesch W Ludwig H Interferon in essential thrombocythaemia Br J Haematol 1991 79 Suppl 1 42 47 1931708
4 Mazzucconi MG Redi R Bernasconi S A long-term study of young patients with essential thrombocythemia treated with anagrelide Haematologica 2004 89 1306 1313 15531452
5 Tefferi A Silverstein MN Petitt RM Mesa RA Solberg LA Jr Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications Semin Thromb Hemost 1997 23 379 383 9263355
6 Proietti R Rognoni A Ardizzone F Maccio S Santagostino A Rognoni G Atypical Takotsubo syndrome during anagrelide therapy J Cardiovasc Med (Hagerstown) 2009 10 546 549 19395976
7 Bildirici U Celikyurt U Ural E Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female Clin Cardiol 2009 32 104 105 19215011
8 Lin GM Chao TY Wang WB Acute coronary syndromes and Anagrelide Int J Cardiol 2007 117 e17 e19 17320215
9 Birgegård G Long-term management of thrombocytosis in essential thrombocythaemia Ann Hematol 2009 88 1 10 18629498
10 Terada H Satoh H Uehara A Multivessel coronary thrombosis, acute myocardial infarction, and no reflow in a patient with essential thrombocythaemia Heart 2000 83 E10 10814644
11 Nurkalem Z Uslu N Gorgulu S Eren M Left main coronary thrombosis with essential thrombocythemia J Thromb Thrombolysis 2006 22 165 167 17111201
12 Steurer M Gastl G Jedrzejczak WW Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile Cancer 2004 101 2239 2246 15476273
13 Penninga E Jensen BA Hansen PB Anagrelide treatment in 52 patients with chronic myeloproliferative diseases Clin Lab Haematol 2004 26 335 340 15485463
14 Birgegård G Björkholm M Kutti J Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders Haematologica 2004 89 520 527 15136214
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.